Skip to main content

February 2023, Vol 13, No 2

Practices and patients are now coming forward to explain how these programs have put individuals, patient assistance programs (PAPs), foundations, and other patient support systems at risk. Read More ›

For the oncology community, social media has fostered a network where patients, caregivers, and their families can connect to medical professionals as equal stakeholders, sharing education, ideas, research, feedback, and reassurance. In this exchange, medical professionals often learn as much as they teach from patients, patients’ families, and other members of the community. Read More ›

Ibrutinib (Imbruvica) may allow patients with newly diagnosed mantle-cell lymphoma (MCL) to forego autologous stem-cell transplantation (ASCT), according to results of the 3-arm randomized TRIANGLE clinical trial presented at the 64th American Society of Hematology Annual Meeting and Exposition. Read More ›

Results from the IFM2017-03 trial showed that a dexamethasone-sparing regimen of daratumumab (Darzalex) plus lenalidomide (Revlimid; DR) was superior to lenalidomide plus dexamethasone (Rd) in terms of response rates and rates of minimal residual disease (MRD) negativity in frail patients with newly diagnosed multiple myeloma. Read More ›

Using circulating tumor cell (CTC) count to guide the choice of first-line treatment—chemotherapy or endocrine therapy—improved overall survival (OS) compared with investigator’s choice of treatment for patients with metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer, according to results from the STIC CTC trial. Read More ›

In conducting the Mini Z survey in 2022, ACCC’s intention was to measure levels of stress and burnout across all the oncology professionals that make up the multidisciplinary cancer care team for the first time, as well as to compare results from these professionals between 2019 and now. Read More ›

These clinical trials represent a selection of key studies currently recruiting patients with primary liver cancers for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Read More ›